A Phase II, 2-stage, 2-arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer

Trial Profile

A Phase II, 2-stage, 2-arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs MK 2206 (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 04 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 19 Mar 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (NCT01307631).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top